• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Grove Instruments Inc. Welcomes William Tamborlane, MD to Scientific Advisory Board

Grove Instruments Inc. Welcomes William Tamborlane, MD to Scientific Advisory Board

October 19, 2011 By MassDevice Contributors Network

For Immediate Release: October 19, 2011

Contact: Arthur Combs, CEO
Cell: 314 341 3444, [email protected]

WORCESTER, MA – Grove Instruments Inc., a medical device company based in Worcester, MA developing the world’s first noninvasive glucometer today announced that William Tamborlane, MD, Professor of Pediatrics, Chief of Pediatric Endocrinology and Deputy Director Yale Center for Clinical Investigation at Yale University is joining the Company’s Scientific Advisory Board. “We’re building a world class Advisory Board to guide the development and clinical testing of our transformative noninvasive glucometer,” said Arthur Combs, CEO of Grove. Bill joins Dr. Antoine Kaldany of the Harvard Medical Faculty Physicians and the Joslin Clinic as well as Dr. Craig Mello, renowned molecular biologist and Nobel Laureate, whose passion for diabetes care emanates from personal family experience.

Dr. Tamborlane’s research effort is primarily directed at the translation of advances in diabetes technology into improved patient care for patients with diabetes. He serves as Co-Chair of the Juvenile Diabetes Foundation Continuous Glucose Monitoring Study Group that has carried out multi-center trials of continuous glucose sensors to improve diabetes care in patients of all ages.

In 2006 Dr. Tamborlane received the prestigious Mary Tyler Moore and S. Robert Levine Excellence in Clinical Research Award from the Juvenile Diabetes Research Foundation International. In 2009 he received the Diabetes Technology Society Leadership Award and in 2010 he was the recipient of the American Diabetes Association’s Outstanding Clinician Physician in Diabetes Award.
“Caring for children and adolescents with type 1 diabetes is a most demanding field of medicine. Dr. William Tamborlane has long been a role model as a dedicated clinician, teacher and innovator in the field. It is a great privilege for me to welcome Dr. Tamborlane to Grove’s Scientific Advisory Board,” said Dr. Tony Kaldany of the Joslin Clinic. Art Combs, Grove CEO said that “this is a propitious time to have such recognized experts advising the company. We’re thrilled to have Bill join the Advisory Board.”

About Grove Instruments

Grove Instruments, Inc. is a privately held pre-market medical device company developing the world’s first noninvasive glucometer with the potential to exceed the ISO standard for blood glucose meters. Grove’s patented technology is based on the seminal concept of the Optical Bridge and is unique among all NIR spectroscopic approaches to noninvasive blood glucose determination. The Company has been recognized for its innovation, technology development and clinical results on 10 separate occasions by the NIH NIDDK with funded SBIR Grants. In 2011, Grove was also recognized by the Massachusetts Life Sciences Center with an Accelerator Award – one of only 4 recipients out of all Boston-area life sciences companies applying in that round. For more information see www.groveinstuments.com or contact Arthur Combs (314 341 344 mobile).

Filed Under: Uncategorized Tagged With: Grove Instruments Inc., Press Release

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy